Amgen’s Imdelltra plus AstraZeneca’s Imfinzi cuts death risk by ~60% in extensive-stage small cell lung cancer

Amgen presented Phase 3 data at ESMO 2026 showing that its bispecific T‑cell engager Imdelltra, when added to AstraZeneca’s checkpoint inhibitor Imfinzi, significantly reduced mortality in extensive‑stage small cell lung cancer.

In the DeLLphi‑305 trial, 563 patients who had completed first‑line therapy with Imfinzi, platinum chemotherapy and etoposide were randomized to receive Imdelltra plus Imfinzi versus Imfinzi alone. At a median follow‑up of 16 months, the combination lowered the risk of death by nearly 60% and extended overall survival by about eight months.

The results met the primary endpoint of overall survival and were published in The New England Journal of Medicine, prompting analysts such as Truist Securities to describe the data as potentially practice‑changing for first‑line maintenance treatment of extensive‑stage SCLC.

These findings could broaden the use of bispecific T‑cell engagers in oncology and may influence Amgen’s pipeline and market positioning.